Literature DB >> 3124752

Active site directed inhibition of a cytosolic beta-glucosidase from calf liver by bromoconduritol B epoxide and bromoconduritol F.

G Legler1, E Bieberich.   

Abstract

Hydrolysis of p-nitrophenyl-beta-D-glucoside by cytosolic beta-glucosidase proceeds with retention of the anomeric configuration. Whereas inactivation of the enzyme by the glucosidase inhibitor conduritol B epoxide (CBE) was extremely slow (ki(max)/Ki 0.57 M-1 min-1) it reacted 130 times more rapidly with 6-bromo-6-deoxy-CBE (Br-CBE). The beta-glucosidase could be labeled with [3H]Br-CBE; incorporation of 1 mol inhibitor/mol enzyme resulted in complete loss of activity. Most of the bound inhibitor was released after denaturation and treatment with ammonia as (1,3,4/2,5,6)-6-bromocyclohexanepentol, thus demonstrating the formation of an ester bond with an active site carboxylate by trans-diaxial opening of the epoxide ring. It was concluded from the Ki values for the epoxide inhibitors and for coduritol B with the cytosolic enzyme and corresponding data for the lysosomal beta-glucosidase that the unusually low reactivity with CBE and Br-CBE is probably due to the inability of the cytosolic enzyme to effectively donate a proton to the epoxide oxygen. An extremely rapid inactivation of the cytosolic beta-glucosidase was caused by bromoconduritol F ((1,2,4/3)-1-bromo-2,3,4-trihydroxycyclohex-5-ene) with ki(max)/Ki 10(5) M-1 min-1. In contrast with the Br-CBE-inhibited enzyme the beta-glucosidase inhibited by bromoconduritol F was subject to spontaneous reactivation with t1/2 approximately 20 min.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3124752     DOI: 10.1016/0003-9861(88)90467-5

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  5 in total

1.  Consequences of beta-glucocerebrosidase deficiency in epidermis. Ultrastructure and permeability barrier alterations in Gaucher disease.

Authors:  W M Holleran; E I Ginns; G K Menon; J U Grundmann; M Fartasch; C E McKinney; P M Elias; E Sidransky
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

2.  Substrate (aglycone) specificity of human cytosolic beta-glucosidase.

Authors:  Jean-Guy Berrin; Mirjam Czjzek; Paul A Kroon; W Russell McLauchlan; Antoine Puigserver; Gary Williamson; Nathalie Juge
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

3.  Identification of a feedback loop involving β-glucosidase 2 and its product sphingosine sheds light on the molecular mechanisms in Gaucher disease.

Authors:  Sophie Schonauer; Heinz G Körschen; Anke Penno; Andreas Rennhack; Bernadette Breiden; Konrad Sandhoff; Katharina Gutbrod; Peter Dörmann; Diana N Raju; Per Haberkant; Mathias J Gerl; Britta Brügger; Hila Zigdon; Ayelet Vardi; Anthony H Futerman; Christoph Thiele; Dagmar Wachten
Journal:  J Biol Chem       Date:  2017-03-03       Impact factor: 5.157

4.  Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function.

Authors:  W M Holleran; Y Takagi; G K Menon; G Legler; K R Feingold; P M Elias
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

5.  In vivo inhibition of beta-glucosidase and beta-mannosidase activity in rats by 2-deoxy-2-fluoro-beta-glycosyl fluorides and recovery of activity in vivo and in vitro.

Authors:  J D McCarter; M J Adam; N G Hartman; S G Withers
Journal:  Biochem J       Date:  1994-07-15       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.